Skip to main content
Journal cover image

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Journal articles  - Journal Article
Claiborne, JP; Li, D; Tsai, H-L; Ghiaur, G; Smith, BD; Levis, MJ; DeZern, AE; Ambinder, AJ; Jain, T; Prince, GT; Gondek, LP; Karantanos, T ...
Published in: Leuk Res
October 2025

BACKGROUND: Blinatumomab has proven efficacy in the frontline, consolidation, and relapsed/refractory settings in B cell acute lymphoblastic leukemia. Its efficacy and safety among patients commonly excluded from clinical trials are unknown. PATIENTS AND METHODS: This single center, retrospective cohort study included patients treated for acute leukemia with blinatumomab with the following pre-existing conditions: liver dysfunction, renal impairment, central nervous system (CNS) conditions, autoimmune disease, solid organ transplantation, or uncontrolled infection. Rates of blinatumomab completion, efficacy outcomes, cytokine release syndrome (CRS), neurotoxicity (ICANS), and adverse events specific to the impaired organ leading to inclusion were assessed. RESULTS: Thirty-four patients were included, and 88 % completed at least one cycle of blinatumomab. One patient stopped prematurely due to toxicity and three due to lack of response in the relapsed/refractory setting. Response rates and survival were similar by treatment setting to those treated in clinical trials. The 60-day cumulative incidence of grade ≥ 2 CRS and ICANS were 23.5 % and 20.8 %, respectively. No excess liver injury, ICANS, autoimmune flares, organ rejection, or infections were observed in cohorts defined by impairment of each system. CONCLUSION: Blinatumomab was successfully administered to the vast majority of patients with a baseline condition that would have led to clinical trial exclusion. Adverse events generally occurred at rates similar to prior clinical trials. These data provide the basis to consider removing certain exclusion criteria from future studies involving blinatumomab, allowing more patients to benefit from its efficacy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Res

DOI

EISSN

1873-5835

Publication Date

October 2025

Volume

157

Start / End Page

108098

Location

England

Related Subject Headings

  • Young Adult
  • Retrospective Studies
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Follow-Up Studies
  • Female
  • Cytokine Release Syndrome
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Claiborne, J. P., Li, D., Tsai, H.-L., Ghiaur, G., Smith, B. D., Levis, M. J., … Webster, J. A. (2025). Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities. Leuk Res, 157, 108098. https://doi.org/10.1016/j.leukres.2025.108098
Claiborne, J Preston, Daniel Li, Hua-Ling Tsai, Gabriel Ghiaur, B Douglas Smith, Mark J. Levis, Amy E. DeZern, et al. “Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.” Leuk Res 157 (October 2025): 108098. https://doi.org/10.1016/j.leukres.2025.108098.
Claiborne JP, Li D, Tsai H-L, Ghiaur G, Smith BD, Levis MJ, et al. Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities. Leuk Res. 2025 Oct;157:108098.
Claiborne, J. Preston, et al. “Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.” Leuk Res, vol. 157, Oct. 2025, p. 108098. Pubmed, doi:10.1016/j.leukres.2025.108098.
Claiborne JP, Li D, Tsai H-L, Ghiaur G, Smith BD, Levis MJ, DeZern AE, Ambinder AJ, Jain T, Prince GT, Gondek LP, Karantanos T, Dalton WB, Gojo I, Webster JA. Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities. Leuk Res. 2025 Oct;157:108098.
Journal cover image

Published In

Leuk Res

DOI

EISSN

1873-5835

Publication Date

October 2025

Volume

157

Start / End Page

108098

Location

England

Related Subject Headings

  • Young Adult
  • Retrospective Studies
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Follow-Up Studies
  • Female
  • Cytokine Release Syndrome